Quote:As a physician who deals with pandemic issues daily I am here to tell you it's as bad as it's ever been. Today 5 of my operating room techs tested positive. Our ICU is now full. The Alpha article downplaying the severity and saying the standard of care is so much better now, well that's because early in the pandemic we were so bad at treating ventilated patients that 80 percent of them died. It's better now but the chances of mortality once on a ventilator is still very high and these patients are spending weeks in the ICUs and are getting tracheotomies sometimes three to four weeks after being in the unit. They are frequently having permanent lung, neurological or kidney damage if they survive. The cost of these hospitalizations is frequently over $100k per patient. We are doing all the state of the art stuff, IV Redesivir, dendron, high tech ventilators, dialysis...
Yeah SOC is better, but it is still is terrible. Don't fall for the short message that SOC has caught up with LL.
I don't know what will happen in the next day or so in regards to EUA, but I can tell you there won't be enough if it gets one. I read all Seaking Alpha article put out today about how Cytodyn is burning through cash, how they haven't applied for OWS, how NP has been inept in trying to get approval and how his CCs are often counterproductive to the SP. I also saw that they owe Samsung millions of dollars they don't have to manufacture and stockpile thousands of doses which are available for use NOW. If only we could get our hands on some in my ICUs here and get these patients off the ventilators. At a cost of $1200 a week if we shorten an ICU stay by only a couple of hours it pays for itself. From the data I have seen, I think it would cut ICU stays in half or better. The bill to Samsung will then be chump change.
I just need to get it, as does every other critical care doctor in the world. I hope the FDA sees this the way I do.
I know the shorts are trolling us and want to drive this company into the ground to make a few bucks, but believe me, the data shows it works and every critical care doctor in the world will want to use it immediately once the statistically significant proof of the CD12 trial is publicized, even if it's stopped early because of statistically significant positive outcomes. Damn the torpedoes.
From Dr Joe Campbell from Hattiesburg, MS on the YMB: As
Top 10 Most Recent News Articles
Innovent's SINTBILO® Hits Primary Endpoint in Study
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth
AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...
Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment
Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...
Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care
Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...
Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue ReadingTop 5 Most Recently Viewed Articles
Equitage Ventures Launches $47.3M Fund for Senior Care Tech
Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...
Continue Reading
Understanding Market Trends: Insights into Chevron Corp's Performance
Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...
Continue Reading
Establishment of Blakely McCrory Hope Fund at Moody Gardens
Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....
Continue Reading
Star-Studded Table Read of 'It's a Wonderful Life' Event
Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...
Continue Reading
Transforming $100 Into Over $1700 with Monolithic Power Systems
Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...
Continue Reading